Posted on October 4, 2013 by Sitemaster
A report published yesterday on the OncLive web site discusses a presentation by Dr. Howard Scher at the 2013 European Cancer Congress in Amsterdam. Dr. Scher reported that a panel of biomarkers could identify men with metastatic, castration-resistant prostate cancer (mCRPC) who were responding well or less well to treatment with abiraterone + prednisone. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, CTC count, LDH, mCRPC, prognosis, survival | 2 Comments »
Posted on July 17, 2012 by Sitemaster
A paper in the Annals of Oncology suggests that treatment with abiraterone acetate may induce a loss of effectiveness of docetaxel-based chemotherapy and that men with metastatic, castration resistant prostate cancer (mCRPC) who do not respond to abiraterone acetate will also not respond to docetaxel-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, docetaxel, enzalutamide, mCRPC, resistance, sequencing | 4 Comments »
Posted on October 6, 2011 by Sitemaster
A videotaped expert commentary by Dr. Johann de Bono on the Medscape Oncology web site (with transcript) discusses four therapies (three now approved in the USA) that have recently demonstrated a survival benefit in the treatment of metastatic, castration-resistant prostate cancer.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, cabazitaxel, radium-223, sipuleucel-T | Leave a comment »
Posted on September 7, 2011 by Sitemaster
Abiraterone acetate (Zytiga®) has been approved for clinical use in European Union nations, according to a media release from Johnson & Johnson issued earlier today. This final approval by the European Commission follows an earlier recommendation for approval issued by the European Medicines Agency (EMEA) at the end of July. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, approval, Europe | Leave a comment »
Posted on August 1, 2011 by Sitemaster
According to a media release issued by Johnson & Johnson late last week, after a priority review, Health Canada has approved abiraterone acetate (Zytiga™) in combination with prednisone for the treatment of men with metastatic, castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel.
Filed under: Drugs in development, Management, Treatment | Tagged: abiraterone acetate, Canada, Zytiga | Leave a comment »
Posted on May 19, 2011 by Sitemaster
Some readers may be interested in in reading a commentary by John Carroll on the FierceBiotech web site, where he discusses whether MDV3100 is going to be able to “match up” to abiraterone acetate — always assuming that MDV3100 can also show a survival benefit in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone acetate, mCRPC, MDV3100 | 2 Comments »
Posted on February 18, 2010 by Sitemaster
On Tuesday this week, three papers about abiraterone acetate were published in the on-line version of the Journal of Clinical Oncology. These articles are reports of data previously presented at various clinical/scientific meetings, but at least they are now available in a peer-reviewed journal. … READ MORE …
Filed under: Drugs in development, Uncategorized | Tagged: abiraterone acetate, castration-resistant prostate cancer, CRPC | 14 Comments »
Posted on May 31, 2009 by Sitemaster
There were probably over 100 posters related to prostate cancer presented at the ASCO meeting today (Sunday, May 31), so you will have to pardon us for not even attempting to report on all this vast variety of data. Rather, we have attempted to select out the papers that seem to offer the most interesting and immediately valuable knowledge for the patient community. … READ MORE …
Filed under: Diagnosis, Drugs in development, Risk | Tagged: abiraterone acetate, PCA3 | Leave a comment »
Posted on April 29, 2009 by Sitemaster
According to a media release from Cougar Biotechnology, a second Phase III clinical trial of abiraterone acetate started today — for men with castration-resistant prostate cancer (CRPC) who have not received chemotherapy. … READ MORE …
Filed under: Drugs in development | Tagged: abiraterone acetate, CRPC, Phase III | 10 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 